Pharmaceutical Safety Review • Moderate Interaction Classification

TUDCA vs Milk Thistle (Silymarin) Prescription Drug Interactions & CYP450 Profile

Systematic analysis of cytochrome P450 enzyme metabolism, renal clearance competition, and clinical contraindications.

Absolute Clinical Contraindications

  • Complete biliary tract obstruction
  • Severe gallstone impaction
  • Acute cholecystitis

Reported Clinical Adverse Events

  • Mild diarrhea or loose stools at TUDCA doses >1,000mg
  • Mild laxative effect from silymarin
  • Mild abdominal cramps

Hepatic Cytochrome P450 (CYP) & Transporter Pathways

Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:

  • CYP3A4 Substrate / Inhibitor: Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
  • Gastrointestinal Transit Modulation: GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
  • Pharmacokinetic Half-Life Clearance: Systemic clearance requires approximately 5 elimination half-lives (TUDCA: approx. 3 hours (circulates via enterohepatic recycling)).

Protocol Audit Links for TUDCA vs Milk Thistle (Silymarin)

← Return to TUDCA vs Milk Thistle (Silymarin) Monograph Calculate Weight Dosage Table → Launch Full Multi-Drug Interaction Checker →